In addition, our observations suggest that additional work is required to assess clinical differences we observed, particularly between ER−/PR+ and ER+/PR− breast cancers, as this information could potentially be used to improve systemic adjuvant treatments. This evidence concerns the gene PGR and breast carcinoma.